Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2004

View Archived Issues

Labopharm to formulate once-daily trazodone

Novel steroid sulphate inhibitor for breast tumor therapy reported

NNC-55-0396: A novel selective T-type Ca2+ channel inhibitor

Promising ORL-1 antagonist for chronic pain therapy

Novel NPY Y1 inhibitor from Bristol-Myers Squibb

Early access program for pirfenidone in IPF

Payment to NeuroSearch for ongoing development of NS-2330

Zambon and BioXell to develop new CXCR3 antagonists

Enrollment under way in ARRIVE registry program

Micrologix Biotech acquires celgosivir rights

Positive results for Columbia's lidocaine vaginal gel for dysmenorrhea

BioTie Therapies reports 2003 progress

Celgene reports 2003 company highlights

BMS highlights 2003 development activities

Novel cannabinoid CB2 agonists and their use reported by Schering-Plough

Merck Frosst presents PDE4 inhibitors for cognition disorders, asthma, etc.

Pfizer presents new ERbeta-selective SERM in a recent patent

Celltech team identifies a novel series of p38 MAP kinase inhibitors

Novel antimalarial agents in early development at Merck

New PPAR agonists and their use reported by GSK researchers

Acutumine and its derivatives exhibit cognition-enhancing properties

Enrollment ceased in phase III NSCLC study of Sarasar

Extension to Vitrase NDA review

Probactrix IBS trial commences enrollment

Chinese approval for phase I trial of Sinovac's SARS vaccine candidate

Neuroprotective effects of GPI-15427 following cardiac arrest

Long therapeutic window for neuroprotection with highly selective kappa-opioid receptor agonists

A 2% green tea extract gel significantly improves damaged and aged facial skin in women

Effective treatment of psychodermatoses with an antidepressant

Therapeutic benefits found for botulinum toxin type A in hyperhidrosis

Phase II results of a G17-DT combination therapy in advanced gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...